Sign In

England confirms 'routine' funding for KEYTRUDA in lung cancer

Patients in England now have "routine" access to MSD's KEYTRUDA (pembrolizumab) for the first-line treatment of lung cancer after a funding agreement between the company and country's National Health Service.